Targeting Chromatin Effector Pygo2 to Enhance Immunotherapy in Prostate Cancer
Zhu, Y.; Zhao, Y.; Wen, J.; Liu, S.; Huang, T.; Hatial, I.; Peng, X.; Janabi, H. A.; Huang, G.; Mittlesteadt, J.; Cheng, M.; Bhardwaj, A.; Ashfeld, B.; Kao, K. R.; Maeda, D. Y.; Dai, X.; Wiest, O.; Blagg, B.; Lu, X.; Cheng, L.; Wan, J.; Lu, X.
Show abstract
The noninflamed microenvironment in prostate cancer represents a barrier to immunotherapy. Genetic alterations underlying cancer cell-intrinsic oncogenic signaling have emerging roles in shaping the immune landscape. Recently, we identified Pygopus 2 (PYGO2) as the driver oncogene for the amplicon at 1q21.3. Here, using transgenic mouse models of metastatic prostate adenocarcinoma, we found that Pygo2 deletion decelerated tumor progression, diminished metastases, and extended survival. Pygo2 loss augmented the infiltration of cytotoxic T lymphocytes (CTLs) and sensitized tumor cells to T cell killing. Mechanistically, Pygo2 orchestrated a p53/Sp1/Kit/Ido1 signaling network to foster a microenvironment hostile to CTLs. Genetic or pharmacological inhibition of Pygo2 enhanced the anti-tumor efficacy of immunotherapies using immune checkpoint blockade, adoptive cell transfer, or myeloid-derived suppressor cell inhibitors. In human prostate cancer samples, Pygo2 expression was inversely correlated with CD8+ T cells. Our results highlight a promising path to improving immunotherapy with targeted therapy for lethal prostate cancer.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Glutamine mimicry suppresses tumor progression through asparagine metabolism in pancreatic ductal adenocarcinoma 97%
- The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1 96%
- Multi-modal digital pathology for colorectal cancer diagnosis by high-plex immunofluorescence imaging and traditional histology of the same tissue section 96%
Similar papers in this journal
Similar papers in this journal
- Combinatorial tumor suppressor inactivation efficiently initiates lung adenocarcinoma with therapeutic vulnerabilities 96%
- Quantitative in vivo analyses reveal a complex pharmacogenomic landscape in lung adenocarcinoma 96%
- Age-associated modulation of TREM1/2- expressing macrophages promotes melanoma progression and metastasis 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.